Nuacht

Applied Clinical Trials Online17 uair an chloig
Overcoming Operational Challenges in Oncology Clinical Trials: Lessons from a Multicentric Study in India
Case study highlights how clinical operations teams can overcome complex regulatory and operational hurdles to finish a trial ...
Applied Clinical Trials Online20 uair an chloig
CARTITUDE-1 Trial Shows Carvykti Achieves Durable, Treatment-Free Remissions in Relapsed or Refractory Multiple Myeloma
Results from the Phase Ib/II CARTITUDE-1 trial demonstrated that a single infusion of Carvykti delivered durable, ...
Applied Clinical Trials Online1 lá
HHS Cancels Moderna Grant for Late-Stage Development of mRNA Vaccine Candidate
Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...
Applied Clinical Trials Online1 lá
How Trump’s Most Favored Nation Policy Could Impact Funding for Clinical Development
In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), discusses ...
Applied Clinical Trials Online1 lá
Phase III MATTERHORN Trial Shows Imfinzi Combo Significantly Improves Event-Free Survival in Resectable Gastric and GEJ Cancers
Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...
Applied Clinical Trials Online2 lá
Tecentriq and Zepzelca Combo Demonstrates Significant Survival Benefit in Phase III Study for Extensive-Stage Small Cell Lung Cancer
In the Phase III IMforte trial, Tecentriq (atezolizumab) and Zepzelca (lurbinectedin) reduced the risk of disease progression ...
Applied Clinical Trials Online2 lá
Phase III BREAKWATER Trial Shows Braftovi-Based Regimen Improves Survival in BRAF V600E-Mutant Metastatic Colorectal Cancer
Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...
Applied Clinical Trials Online3 lá
Rising API Tariffs Are Forcing Pharma to Shift R&D Resources
In this video interview, Ron Lanton, partner, Lanton Law, highlights how tariffs on active pharmaceutical ingredients could ...